

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 May 2017 (04.05.2017)

(10) International Publication Number
WO 2017/075173 A3

(51) International Patent Classification:

A61K 39/395 (2006.01) *A61P 27/02* (2006.01)
C07K 16/18 (2006.01)

DNA Way, South San Francisco, California 94080 (US).
TESAR, Devin; 1 DNA Way, South San Francisco, California 94080 (US). **SCHEER, Justin M.**; 1 DNA Way, South San Francisco, California 94080 (US). **DION, Michelle**; 1 DNA Way, South San Francisco, California 94080 (US).

(21) International Application Number:

PCT/US2016/059048

(74) Agents: **SCARR, Rebecca B.** et al.; MCNEILL BAUR PLLC, 500 W. Silver Spring Drive, Suite K-200, Glendale, Wisconsin 53217 (US).

(22) International Filing Date:

27 October 2016 (27.10.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/249,166 30 October 2015 (30.10.2015) US
62/250,995 4 November 2015 (04.11.2015) US

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(71) Applicant (for all designated States except AL, AT, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, KW, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR): **GEN-ENTECH, INC.** [US/US]; 1 DNA Way, South San Francisco, California 94080 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

(71) Applicant (for AL, AT, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR only): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(72) Inventors: **KELLEY, Robert F.**; 1 DNA Way, South San Francisco, California 94080 (US). **SHATZ, Whitney**; 1

[Continued on next page]

(54) Title: ANTI-FACTOR D ANTIBODIES AND CONJUGATES

Antibody	Name	On-Rate (M ⁻¹ s ⁻¹)	Off-Rate (s ⁻¹)	KD (pM) hF0 (Human)	KD (pM) cF0 (cynom)	FRET IC50 (pM)	Viscosity on PEG-octamer	Viscosity on (Fab; No PEG)	Solubility (PBS pH 7.4)	MA Solubility (PBS pH 7.4)
hu20D12.v1.N54S	hu20D12.v2.0	1.4e7	5.5e4	39	152	51, 59		12 cP @ 260 mg/ml	Clear @ 292 mg/ml	
hu20D12.v1.N54S.G68D	hu20D12.v2.2	1.5e7	9.5e4	65						
hu20D12.v1.N54S.G56E	hu20D12.v2.4	1.7e7	4.9e4	28						
hu20D12.v1.N54S.T53Y	hu20D12.v2.5	1.7e7	7.3e4	45						
hu20D12.v1.N54S.Y49S	hu20D12.v2.6	2.1e6	3.5e4	143						
hu20D12.v1.N54S.Y49R	hu20D12.v2.7	1.1e7	5.5e4	49						
hu20D12.v1.N54S.Y49Q	hu20D12.v2.8	6.6e7	4e3	61						
hu20D12.v1.N54S.Y49R	hu20D12.v2.1	1.2e7	8.1e5	<10(6.8)	17	33, 32	288 cP @ 201 mg/ml	7.1 cP @ 177 mg/ml	Clear @ 260 mg/ml	0.443 OD @ 150 mg/ml
hu20D12.v1.N54S.E69W	hu20D12.v2.9	3.4e7	6.3e3	185						
hu20D12.v1.N54S.Y55K	hu20D12.v2.10	5e7	3e-2	6000						
hu20D12.v1.N54S.Y58R	hu20D12.v2.11	5e7	3e-2	10000						
hu20D12.v1.N54S.Y49R.T53Y	hu20D12.v2.12	1.8e7	1.5e4	<10(8.3)						
hu20D12.v1.N54S.N82E.Y49R	hu20D12.v2.13	4.1e7	1.3e4	<10(3.1)						
hu20D12.v1.N54S.Y49R.G56E	hu20D12.v2.14	1.5e7	8e-5	<10(5.3)	50	25				
hu20D12.v1.N54S.Y49R.T53Y	hu20D12.v2.15	1.9e7	9e-5	<10(3.2)	27	24				
N54E										
hu20D12.v1.N54S.Y49R.T53Y.G56D	hu20D12.v2.3	1.2e7	2.3e5	<10(2.4)	24	25, 31, 31	577 cP @ 194 mg/ml			
AFD.y'4		2.0e7	2.1e4	10.5	24	21, 28		14.4 cP @ 261 mg/ml		
Empalizumab		0.9e7	2.1e4	23.3	56	25, 34, 26	979 cP @ 117 mg/ml	21 cP @ 240 mg/ml	Precipitates @ 227 mg/ml	Precipitates @ 150 mg/ml; no OD value

FIG. 11

(57) Abstract: The invention provides anti-Factor D antibodies and conjugates and methods of using the same.

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, — *with sequence listing part of description (Rule 5.2(a))*
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

(88) **Date of publication of the international search report:**
27 July 2017

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

INTERNATIONAL SEARCH REPORT**Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)**

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. forming part of the international application as filed:
 - in the form of an Annex C/ST.25 text file.
 - on paper or in the form of an image file.
 - b. furnished together with the international application under PCT Rule 13~~ter~~.1(a) for the purposes of international search
 - only in the form of an Annex C/ST.25 text file.
 - c. furnished subsequent to the international filing date for the purposes of international search only:
 - in the form of an Annex C/ST.25 text file (Rule 13~~ter~~.1(a)).
 - on paper or in the form of an image file (Rule 13~~ter~~.1(b) and Administrative Instructions, Section 713).
2. In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fees, this Authority did not invite payment of additional fees.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2016/059048

A. CLASSIFICATION OF SUBJECT MATTER
 INV. A61K39/395 C07K16/18 A61P27/02
 ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, EMBASE, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2008/147883 A1 (GENENTECH INC [US]; HASS PHILIP [US]; JIANGPING YIN [US]; KATSCHKE KENN) 4 December 2008 (2008-12-04) cited in the application page 24, line 26 - page 29, line 29; claims; examples; sequences 1,2 page 32, line 13 - page 34, line 19	1-10, 12-18, 25-40, 83-110
Y		20,21, 41-82
A		11,19, 22-24
	----- -/-	

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
8 May 2017	19/06/2017
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Loubradou, Gabriel

INTERNATIONAL SEARCH REPORT

International application No PCT/US2016/059048

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	JAMES T. PATTERSON ET AL: "Improving the Serum Stability of Site-Specific Antibody Conjugates with Sulfone Linkers", BIOCONJUGATE CHEMISTRY, vol. 25, no. 8, 20 August 2014 (2014-08-20), pages 1402-1407, XP055338868, ISSN: 1043-1802, DOI: 10.1021/bc500276m abstract; figure 1 -----	20,21
Y	JEVSEVAR SIMONA ET AL: "PEGylation of antibody fragments for half-life extension", METHODS IN MOLECULAR BIOLOGY, vol. 901, 1 January 2012 (2012-01-01), pages 233-246, XP009169915, ISSN: 1940-6029 ISBN: 978-1-61779-291-5 abstract page 236, paragraph 2 - page 237, last paragraph -----	41-82
Y	VUGMEYSTER Y ET AL: "Pharmacokinetic, biodistribution, and biophysical profiles of TNF nanobodies conjugated to linear or branched poly(ethylene glycol)", BIOCONJUGATE CHEMISTRY, vol. 23, no. 7, 18 July 2012 (2012-07-18), pages 1452-1462, XP002735223, ISSN: 1043-1802, DOI: 10.1021/BC300066A [retrieved on 2012-06-25] abstract; figure 1 -----	41-82
Y	EP 2 267 028 A2 (DOMANTIS LTD [GB]) 29 December 2010 (2010-12-29) page 6, paragraph [0327] page 37, paragraph [0437] - page 43, paragraph [0464]; figures 10,11; examples -----	41-82
Y	CHANDRASEKAR DURAIRAJ ET AL: "Prediction of Vitreal Half-Life Based on Drug Physicochemical Properties: Quantitative Structure-Pharmacokinetic Relationships (QSPKR)", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, vol. 26, no. 5, 8 October 2008 (2008-10-08), pages 1236-1260, XP019686076, ISSN: 1573-904X page 1255, right-hand column, last paragraph - page 1256, left-hand column, paragraph 1 ----- -/-	41-82

INTERNATIONAL SEARCH REPORT

International application No PCT/US2016/059048

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HANIEH KHALILI ET AL: "Fab-PEG-Fab as a Potential Antibody Mimetic", BIOCONJUGATE CHEMISTRY, vol. 24, no. 11, 27 September 2013 (2013-09-27), pages 1870-1882, XP055096654, ISSN: 1043-1802, DOI: 10.1021/bc400246z abstract; figure 1 -----	41-82
A	WO 2009/134711 A1 (GENENTECH INC [US]; HUANG ARTHUR J [US]; KELLEY ROBERT F [US]; LOWMAN) 5 November 2009 (2009-11-05) claims; examples -----	1-110
Y,P	WO 2015/168468 A1 (GENENTECH INC [US]; HOFFMANN LA ROCHE [CH]) 5 November 2015 (2015-11-05) page 31, paragraph [000112] - paragraph [000113]; examples -----	41-82
A	WO 2014/008218 A1 (SQUIBB BRISTOL MYERS CO [US]) 9 January 2014 (2014-01-09) page 1, paragraph 2; figure 3; examples -----	1,2,4-6, 8-10, 12-18, 20,21, 25-110
A	US 2015/259419 A1 (LIU YUE [US] ET AL) 17 September 2015 (2015-09-17) example 6 -----	1,2,4-6, 8-10, 12-18, 20,21, 25-110
A	WO 2011/008092 A2 (AIMM THERAPEUTICS BV [NL]; GENENTECH INC [US]; BEAUMONT TIM [NL]; KWAK) 20 January 2011 (2011-01-20) example 4 -----	1,2,4-6, 8-10, 12-18, 20,21, 25-110
A	WO 2006/083971 A2 (GENENTECH INC [US]; ADAMS CAMELLIA W [US]) 10 August 2006 (2006-08-10) example 1; table 1 -----	1,2,4-6, 8-10, 12-18, 20,21, 25-110

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2016/059048

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2008147883	A1	04-12-2008	AR 066660 A1 AU 2008256835 A1 BR PI0811142 A2 CA 2683498 A1 CN 101754980 A CN 104367999 A CY 1116062 T1 DK 2152755 T3 EP 2152755 A1 ES 2533242 T3 HK 1139161 A1 HK 1207327 A1 HR P20150281 T1 IL 201476 A JP 5416695 B2 JP 2010528047 A JP 2014087346 A JP 2016145205 A KR 20100033973 A PE 02942009 A1 PH 12013500992 A1 PT 2152755 E RU 2009147744 A RU 2014113046 A SG 10201401404R A SI 2152755 T1 TW 200904471 A TW 201417829 A US 2009181017 A1 US 2011282034 A1 US 2013052685 A1 US 2013302333 A1 US 2016272726 A1 WO 2008147883 A1 ZA 200907028 B	02-09-2009 04-12-2008 23-12-2014 04-12-2008 23-06-2010 25-02-2015 08-02-2017 02-03-2015 17-02-2010 08-04-2015 30-10-2015 29-01-2016 10-04-2015 30-11-2016 12-02-2014 19-08-2010 15-05-2014 12-08-2016 31-03-2010 27-03-2009 25-01-2016 01-04-2015 27-06-2011 10-10-2015 28-08-2014 29-05-2015 01-02-2009 16-05-2014 16-07-2009 17-11-2011 28-02-2013 14-11-2013 22-09-2016 04-12-2008 29-12-2010
EP 2267028	A2	29-12-2010	NONE	
WO 2009134711	A1	05-11-2009	AR 071510 A1 AR 086272 A2 AU 2009241348 A1 CA 2720853 A1 CA 2908470 A1 CN 102066419 A CN 103724433 A CO 6331346 A2 CR 11817 A CY 1116982 T1 DK 2283041 T3 EC SP10010637 A EP 2283041 A1 EP 3002295 A1 ES 2552817 T3 HK 1147503 A1 HK 1193111 A1 HR P20151259 T1 JP 5636359 B2 JP 5931008 B2	23-06-2010 04-12-2013 05-11-2009 05-11-2009 05-11-2009 18-05-2011 16-04-2014 20-10-2011 13-01-2011 05-04-2017 07-12-2015 30-12-2010 16-02-2011 06-04-2016 02-12-2015 27-05-2016 25-11-2016 18-12-2015 03-12-2014 08-06-2016

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2016/059048

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		JP 2011521623 A	28-07-2011
		JP 2013231045 A	14-11-2013
		KR 20110004451 A	13-01-2011
		KR 20130084330 A	24-07-2013
		MA 32300 B1	02-05-2011
		NZ 588457 A	21-12-2012
		NZ 603492 A	30-05-2014
		NZ 621103 A	30-10-2015
		PE 08062014 A1	17-07-2014
		PE 17832009 A1	04-12-2009
		PT 2283041 E	24-11-2015
		RU 2010148423 A	10-06-2012
		SG 189756 A1	31-05-2013
		SG 10201608305S A	29-11-2016
		SI 2283041 T1	31-12-2015
		TW 200944234 A	01-11-2009
		TW 201437230 A	01-10-2014
		US 2009269338 A1	29-10-2009
		US 2012328613 A1	27-12-2012
		US 2014065137 A1	06-03-2014
		US 2014212433 A1	31-07-2014
		US 2016145349 A1	26-05-2016
		WO 2009134711 A1	05-11-2009
<hr/>			
WO 2015168468	A1 05-11-2015	AU 2015253042 A1	20-10-2016
		CA 2944712 A1	05-11-2015
		CN 106536561 A	22-03-2017
		EA 201692109 A1	31-03-2017
		EP 3137503 A1	08-03-2017
		KR 20160147855 A	23-12-2016
		PE 14402016 A1	26-01-2017
		PH 12016502015 A1	16-01-2017
		SG 11201608868P A	29-11-2016
		TW 201623337 A	01-07-2016
		US 2016017052 A1	21-01-2016
		WO 2015168468 A1	05-11-2015
<hr/>			
WO 2014008218	A1 09-01-2014	AR 091649 A1	18-02-2015
		AU 2013286914 A1	29-01-2015
		CA 2877746 A1	09-01-2014
		CL 2014003637 A1	27-03-2015
		CN 104411723 A	11-03-2015
		CO 7170127 A2	28-01-2015
		EA 201590138 A1	30-07-2015
		EP 2867258 A1	06-05-2015
		HK 1207386 A1	29-01-2016
		JP 2015527880 A	24-09-2015
		KR 20150023909 A	05-03-2015
		NZ 628528 A	29-07-2016
		PE 02212015 A1	19-02-2015
		PH 12014502854 A1	23-02-2015
		SG 10201610960Y A	27-02-2017
		SG 11201408780X A	29-01-2015
		TN 2014000536 A1	30-03-2016
		TW 201406784 A	16-02-2014
		US 2014093511 A1	03-04-2014
		US 2015307609 A1	29-10-2015
		UY 34887 A	31-12-2013

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2016/059048

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
		WO	2014008218 A1	09-01-2014
US 2015259419	A1	17-09-2015	AU 2015228454 A1 CA 2942233 A1 CN 106132990 A CU 20160133 A7 EA 201691836 A1 EP 3116912 A1 JP 2017510567 A KR 20160131061 A PE 12102016 A1 PH 12016501760 A1 SG 11201606274X A TW 201623331 A US 2015259419 A1 WO 2015136470 A1	11-08-2016 17-09-2015 16-11-2016 02-02-2017 30-12-2016 18-01-2017 13-04-2017 15-11-2016 02-12-2016 07-11-2016 30-08-2016 01-07-2016 17-09-2015 17-09-2015
WO 2011008092	A2	20-01-2011	AR 077756 A1 AU 2010271582 A1 AU 2016250398 A1 BR 112012000953 A2 CA 2768204 A1 CN 102666583 A CN 105440133 A EA 201390967 A1 EP 2454284 A2 IL 217497 A IL 238074 A JP 2012533293 A JP 2016135771 A KR 20120065326 A NZ 598063 A NZ 616921 A SG 177653 A1 TW 201107470 A TW 201610153 A US 2011020323 A1 US 2012157665 A1 US 2013253175 A1 US 2013261293 A1 US 2014235828 A1 US 2015376266 A1 US 2016222096 A1 US 2017067880 A1 WO 2011008092 A2 ZA 201200363 B	21-09-2011 01-03-2012 17-11-2016 22-11-2016 20-01-2011 12-09-2012 30-03-2016 30-01-2014 23-05-2012 30-11-2015 30-06-2016 27-12-2012 28-07-2016 20-06-2012 25-07-2014 26-06-2015 28-02-2012 01-03-2011 16-03-2016 27-01-2011 21-06-2012 26-09-2013 03-10-2013 21-08-2014 31-12-2015 04-08-2016 09-03-2017 20-01-2011 25-06-2014
WO 2006083971	A2	10-08-2006	AT 526987 T AU 2006210779 A1 BR PI0606891 A2 CA 2594918 A1 EP 1844077 A2 ES 2374301 T3 HK 1109638 A1 IL 184617 A JP 5886509 B2 JP 2008532487 A JP 2013027407 A	15-10-2011 10-08-2006 21-07-2009 10-08-2006 17-10-2007 15-02-2012 17-08-2012 30-05-2013 16-03-2016 21-08-2008 07-02-2013

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2016/059048

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		JP 2015133985 A	27-07-2015
		KR 20070102585 A	18-10-2007
		NZ 556478 A	25-02-2011
		US 2006269554 A1	30-11-2006
		US 2007031414 A1	08-02-2007
		US 2012087922 A1	12-04-2012
		WO 2006083971 A2	10-08-2006

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 3, 7, 11, 19, 22-24(completely); 1, 2, 4-6, 8-10, 12-18, 20, 21, 25-110(partially)

Subject-matter of claims 1 to 110 as far as X2 is R
(position 49 of the light chain is arginine; see claim 3).
This invention includes the antibodies hu20D12.v2.1,
hu20D2012.v2.3, hu20D2012.v2.12, hu20D2012.v2.13,
hu20D2012.v2.14 and hu20D2012.v2.15.

2. claims: 1, 2, 4-6, 8-10, 12-18, 20, 21, 25-110(all partially)

Subject-matter of claims 1, 2, 4 to 6, 8 to 10, 12 to 18,
20, 21 and 25 to 110 as far as X2 is not R and as far as the
HVRs correspond to one of the alternatives a), b) and d) to
1) of claim 6.

3. claims: 1, 2, 4-6, 8-10, 12-18, 20, 21, 25-110(all partially)

Subject-matter of claims 1, 2, 4 to 6, 8 to 10, 12 to 18,
20, 21 and 25 to 110 as far as the antibody corresponds to
the alternative g) of claim 10 (the variable regions of the
antibody hu20D12.v1).
